The anticancer effects of HDAC inhibitors require the immune system

Oncoimmunology. 2014 Jan 1;3(1):e27414. doi: 10.4161/onci.27414.

Abstract

Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.

Keywords: HDACi; anticancer immunity; anticancer therapy; epigenetic regulatory agent; immunogenic cell death; immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't